Diabetes News You Can Use
Annual food insecurity report canceled by USDA
The Trump administration has decided to terminate the annual federal report on food insecurity, citing it as redundant and politicized. The USDA said the report, initiated during the Clinton administration, has not effectively reflected changes in food insecurity despite increased SNAP spending. The USDA said it plans to issue one final report on hunger in October.
Full Story: CNN (9/21), The Seattle Times (tiered subscription model) (9/21), The Washington Post (9/21)
Study links prediabetes to faster measured GFR decline
Prediabetes is associated with a faster decline in measured glomerular filtration rate but not in estimated GFR, according to a study in Kidney International. Researchers observed a significant decline in GFR among participants with prediabetes over a median of 10.7 years, but no significant association was found between prediabetes and estimated GFR decline using creatinine and cystatin C.
Full Story: DocWire News (9/21)
Kidney failure risk is high with diabetes, low eGFR
A population-based study of EHR data for 618,739 people in the Clinical Journal of the American Society of Nephrology found that adults with diabetes and lower estimated glomerular filtration rates had higher risk of death and kidney failure. “It is time to de-silo nephrology and move upstream in CKD care to provide patient-centered holistic treatments that save kidneys, hearts and lives,” said Dr. Katherine Tuttle, an author of the study.
Full Story: Healio (free registration) (9/22)
Survey finds physician stress returns to pandemic levels
A survey by the Physicians Foundation found that 57% of physicians reported inappropriate feelings of anger, tearfulness or anxiety in the past year, up from 50% in 2024 and 2023 but similar to levels reported in 2021 and 2022. The survey found 46% of physicians said they have withdrawn from family, friends or co-workers, 34% have felt hopeless or without purpose, and 55% have felt debilitating stress.
Full Story: MedPage Today (free registration) (9/18)
Tirzepatide may work as well as dulaglutide for CV prevention
Tirzepatide may be as effective as dulaglutide in preventing cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, according to a study presented at the annual meeting of the European Association for the Study of Diabetes. The study also found tirzepatide was associated with a reduced risk of all-cause mortality compared with dulaglutide.
Full Story: Healio (free registration) (9/19)
Baricitinib benefits end after discontinuation
The benefits of the JAK inhibitor baricitinib for patients with new-onset type 1 diabetes were lost after discontinuation, according to two-year data from the Phase 2 BANDIT trial. The findings were presented at the European Association for the Study of Diabetes annual meeting.
Full Story: MedPage Today (free registration) (9/18)
Low-dose antithymocyte globulin may preserve beta cells
A 0.5 mg/kg dose of antithymocyte globulin was as effective as a 2.5 mg/kg dose in preserving beta-cell function in children and young adults with newly diagnosed type 1 diabetes, according to a Phase 2 study in The Lancet. The lower dose was associated with fewer adverse events.
Full Story: Healio (free registration) (9/18)
BMI screening helps identify excess adiposity
A study published in JAMA Pediatrics found that body mass index screening identified excess adiposity in more than 98% of youths with obesity. The study, involving 183 participants ages 8 to 17, also showed that the screening found excess adiposity in up to 32.5% of youth without obesity. Researchers noted that anthropometric measures, such as waist-height ratio, were as effective as DEXA scans in confirming excess adiposity.
Full Story: Medscape (9/8)
44% of people with diabetes remain undiagnosed
A study in The Lancet Diabetes & Endocrinology found that 44% of people aged 15 and older with diabetes are undiagnosed globally, with younger individuals and those in low- to middle-income countries at higher risk. The study emphasizes the importance of early diagnosis to prevent complications such as heart disease and kidney failure.
Full Story: CNN (9/8)
Semaglutide, tirzepatide may benefit patients with HFpEF
Tirzepatide and semaglutide are associated with a significant reduction in all-cause mortality and hospitalizations for heart failure among patients who have heart failure with preserved ejection fraction, obesity and type 2 diabetes, according to a study presented at the European Society of Cardiology and published in JAMA. “Both semaglutide and tirzepatide are well known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and type 2 diabetes by reducing adverse heart failure outcomes,” researcher Nils Kruger said.
Full Story: Cardiovascular Business (9/2)
Diabetes Research Center
Related News
Congratulations to this year’s funding awardees
Congratulations to this year’s funding awardees: Dr. Nicholas Chavkin and Dr. Stephen McCartney have been awarded Pilot and Feasibility awards and Ms. Jocelyn Cervantes has been awarded the Stroum Graduate Fellowship award.
NIDDK 75th Anniversary
In celebration of the 75th anniversary of NIDDK, Diabetes Care and Diabetes have published a compendium of ten articles that highlight just a few of the major contributions NIIDK has fostered through its support of research. These articles provide a broad, but clearly not complete, view of the results that have been achieved through their fostering of science across the country. Included amongst these is a paper by members of NIDDK about the research centers including the Diabetes Research Centers Program. There is also an editorial that celebrates NIDDK and at the same times raises concerns about the future of research and public health related to diabetes given the current discussion about the funding and restructuring of NIDDK and CDC.
DRC Affiliate Edward Boyko is Co-Chair of New Diabetes Atlas
DRC affiliate, Edward Boyko, professor (General Internal Medicine) is co-chair of the new edition of the International Diabetes Federation (IDF) Diabetes Atlas. As the number of people living with diabetes continues to rise, the latest IDF Diabetes Atlas emphasizes the urgent need for improved prevention, early detection and intervention to tackle the burden diabetes places on individuals, communities, health systems and economies.
Learn more on our news site.
CVTMC Director Karin Bornfeldt Announced as 2025 American Society for Biochemistry and Molecular Biology Fellow
The American Society for Biochemistry and Molecular Biology (ASBMB) announced that CVTMC Director Karin Bornfeldt, professor (Metabolism, Endocrinology and Nutrition), has been named among its 2025 class of fellows. Designation as a fellow recognizes commitment to the ASBMB through a history of exceptional and sustained service to the society as well as impactful accomplishments in research, education, mentorship, and service to the scientific community. Twenty-four fellows were selected this year. Read more here.
Affiliate Anne Manicone receives Pilot Award
Affiliate Anne Manicone, professor (Pulmonary, Critical Care, and Sleep Medicine) received a Pilot Project Award, “Identifying Novel Compounds to Polarize Macrophages toward Reparative States,” from the parent P30 Grant, “Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era,” funded by NIH/NIDDK. This 2-year award will provide $264,000 towards developing new strategies to target chronic inflammation seen in people with Cystic Fibrosis.